Affiliated Managers Group (AMG)
(Real Time Quote from BATS)
$160.90 USD
+1.32 (0.83%)
Updated Apr 26, 2024 10:59 AM ET
2-Buy of 5 2
A Value F Growth B Momentum B VGM
Price, Consensus and EPS Surprise
AMG 160.90 +1.32(0.83%)
Will AMG be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMG
Zacks.com featured highlights include Lakeland Industries, PBF Energy, Affiliated Managers, Barrett Business Services and JAKKS Pacific
Ameris Bancorp (ABCB) Q1 Earnings and Revenues Beat Estimates
AMG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pick These 5 Low Price-to-Sales Stocks to Stay Profitable
Are Investors Undervaluing AllianceBernstein (AB) Right Now?
Is Kinsale Capital Group (KNSL) Stock Outpacing Its Finance Peers This Year?
Other News for AMG
Third Avenue Real Estate Value UCITS Named Best Global Real Estate Fund by LSEG Lipper
Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN)
Affiliated Managers Group Is Undervalued Against Peer Group
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
Buy Rating on Amgen: Tezspire’s Market Potential in COPD Treatment Undervalued